Xiaohua Liao

Xiaohua Liao

Auto-generated profile, based on publicly available information

Xiaohua Liao

Department of Nephrology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
YJYupeng Jiang
Yupeng Jiang
FXFeifei Xie
Feifei Xie
XLXin Lv
Xin Lv
SWShuting Wang
Shuting Wang
XLXiaohua Liao
Xiaohua Liao
LTLijian Tao
Lijian Tao
Diabetic kidney disease (DKD) is a major cause of end stage renal diseases worldwide. Despite successive interventions for delaying the progression of DKD, current treatments cannot reverse the pathological progression. Mefunidone (MFD) is a new compound with potent antifibrotic properties, but the effect of MFD on DKD remains unknown. Therefore, we investigated the protective effects of MFD in both models of the db/db type 2 diabetes (T2D) and streptozotocin (STZ)‐induced type 1 diabetes (T1D) models. Compared with the model group, MFD treatment significantly reduced pathological changes observed by PAS staining, PASM staining, and Masson staining in vivo. To further elucidate the potential mechanisms, we discovered MFD treatment notably restored podocyte function, alleviated inflammation, abated ROS generation, inhibited the TGF‐β1/SAMD2/3 pathway, suppressed the phosphorylation levels of MAPKs (ERK1/2, JNK, and P38), and reduced epithelial‐to‐mesenchymal transition(EMT). In conclusion, these findings demonstrate the effectiveness of MFD in diabetic nephropathy and elucidate its possible mechanism.

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
XLXiaohua Liao
Xiaohua Liao
XLXin Lv
Xin Lv
YZYan Zhang
Yan Zhang
YHYuanyuan Han
Yuanyuan Han
JLJiajia Li
Jiajia Li
YXYanyun Xie
Yanyun Xie
Objective. Mitochondrial damage contributes to extracellular matrix (ECM) deposition and renal fibrosis. In this study, we aimed (1) to investigate whether fluorofenidone (AKF‐PD) can attenuate mitochondrial damage in two renal fibrosis models: unilateral ureteral obstruction (UUO) and renal ischemia‐reperfusion injury (IRI), and (2) to explore the underlying mechanism. Method. Mitochondrial damage and renal lesions were analyzed in the UUO and IRI models. Mitochondrial energy metabolism, mitochondrial biogenesis, and oxidative stress were measured to assess the effect of AKF‐PD on mitochondrial damage and to explore the underlying mechanism. In addition, HK‐2 cells were stimulated with TGF‐β with and without AKF‐PD. The mitochondrial morphology, mtROS, ATP contents, and redox‐related proteins were then examined. Results. In both UUO and IRI models, AKF‐PD relieved renal fibrosis, maintained mitochondrial structure, and increased mitochondrial DNA copy numbers. The protection was associated with (1) sustaining mitochondrial energy metabolism, evident by elevations of tricarboxylic acid (TCA) cycle enzymes and mitochondrial respiratory chain complexes; (2) improving mitochondrial biogenesis with increases of TFAM, NRF1, PGC‐1α, and SIRT1; and (3) reducing mitochondrial oxidative stress likely via regulating SOD2, SIRT3, and NOX4 expressions. In HK‐2 cells treated with TGF‐β, AKF‐PD protected mitochondria along with improving mitochondrial morphology, enhancing ATP production, reducing mtROS, and regulating SOD2, SIRT3, and NOX4 expression. Conclusion. We demonstrate that AKF‐PD inhibited renal fibrosis at least in part via protecting mitochondria from damages developed in the UUO and IRI models. The mitochondrial protection was associated with sustaining mitochondrial energy metabolism, improving mitochondrial biogenesis, and reducing mitochondrial oxidative stress. This research verified the protective effect of AKF‐PD on mitochondria in the UUO and IRI models and elaborated the underlying mechanism.

1 January 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
XLXiaohua Liao
Xiaohua Liao
YJYupeng Jiang
Yupeng Jiang
QDQin Dai
Qin Dai
YYYUE YU
YUE YU
Yan ZhangYan Zhang
Yan Zhang
LTLijian Tao
Lijian Tao